Decyzja FDA – dopuszczenie projektu SEL24 do badań klinicznych
TitleFile
Raport bieżący ESPI 28/2016
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy